Ayala Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of Listeria monocytogenes (Lm)- technology antigen delivery products based on a platform technology that utilizes live attenuated Lm, bioengineered to secrete antigen/adjuvant fusion proteins. Its Listeria-based immunotherapies are designed for antigen delivery through a process of insertion of multiple copies of the tLLO-fusion protein into each extrachromosomal protein expression and secretion plasmid that makes and secretes the target protein right Inside the patient’s antigen presenting cells to initiate and/or boost their immune response. It conducts clinical studies of Lm Technology immunotherapies in early prostate cancer. It identifies and works with collaborators and licensees for these programs and others for first-generation Lm immunotherapies, such as ADXS-HPV (AXAL) for HPV-associated cancer and ADXS-HER-2 for pediatric osteosarcoma.